Genus PLC
LSE:GNS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Genus PLC
Genus PLC
Total Equity
Genus PLC
Total Equity Peer Comparison
CNTA
EXAI
AUTL
BCYC
IMCR
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Genus PLC
LSE:GNS
|
Total Equity
£574.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
7%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Total Equity
$236.2m
|
CAGR 3-Years
324%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Total Equity
£355.7m
|
CAGR 3-Years
64%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Total Equity
$111.5m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Equity
$356m
|
CAGR 3-Years
36%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Equity
£368.8m
|
CAGR 3-Years
88%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
See Also
What is Genus PLC's Total Equity?
Total Equity
574.8m
GBP
Based on the financial report for Dec 31, 2023, Genus PLC's Total Equity amounts to 574.8m GBP.
What is Genus PLC's Total Equity growth rate?
Total Equity CAGR 10Y
7%
Over the last year, the Total Equity growth was -1%. The average annual Total Equity growth rates for Genus PLC have been 5% over the past three years , 3% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
